•
China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has released its financial results for the third quarter of 2024. The company reported Q3 revenues of RMB 128.6 million (USD 18.3 million), marking a year-on-year (YOY) increase of 0.8%. Research and development (R&D) expenses saw a significant decline of 41.3% YOY,…
•
Denmark-based pharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has revealed its financial results for the third quarter and the first three quarters of 2024. For the three-month period, revenues increased by 18% year-on-year (YOY) in constant currency terms to DKK 5.722 billion (USD 805 million). Over the nine-month period, sales…
•
US-Irish medical device company Medtronic (NYSE: MDT) has announced its financial results for the second quarter (Q2) of fiscal year 2025, which concluded on October 25, 2024. The company reported a total revenue of USD 8.403 billion for the period, marking a 5.0% increase on an organic basis. Cardiovascular Portfolio…
•
Merck KGaA (NYSE: MRK), the German multinational science and technology company, has released its financial results for the third quarter of 2024, reporting net sales of EUR 5.266 billion (USD 5.55 billion), marking an organic growth of 3.8%. The company’s performance reflects a steady increase in sales across its business…
•
US-based biopharmaceutical company FibroGen Inc. (NASDAQ: FGEN) has released its Q3 2024 financial report, showing revenues of USD 46.3 million for the quarter, a 15% year-on-year (YOY) increase. The net loss narrowed significantly to USD 17.1 million, compared to USD 63.6 million during the same period last year. As of…
•
UK-based pharmaceutical giant AstraZeneca Inc. (AZ, NASDAQ: AZN) has reported its financial performance for the Q3 2024 period, showing a robust 21% year-on-year (YOY) increase in total revenues to USD 13.565 billion at constant exchange rates. Product sales also saw a significant 20% growth to USD 12.947 billion. Business Unit…
•
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a China-based biotech company, has released its Q3 2024 financial results, achieving total operating revenue of USD 1.002 billion, marking a 28% year-on-year (YOY) increase. Product revenue within this total saw a substantial 67% YOY rise to USD 993 million. For the…
•
Germany-based Bayer AG (ETR: BAYN) has released its Q3 2024 financial results, reporting a 0.6% year-on-year (YOY) growth in constant currency terms to EUR 9.968 billion (USD 10.59 billion) in global group sales. This growth was driven by strong performances in the Pharmaceuticals and Consumer Healthcare segments, offsetting a decline…
•
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its Q3 2024 financial report, showcasing robust growth and providing updates on recent product highlights and corporate developments. Revenue Growth and Product PerformanceDuring Q3, Zai Lab reported product net revenues of USD 101.8 million, a 46% year-on-year (YOY) increase…
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced its financial results for the third quarter of 2024, reporting a significant increase in revenue. The company generated USD 160 million in revenue for the three months ended September 30, 2024, marking a 67% year-on-year (YOY) increase. Revenue Breakdown and Key DriversCollaboration…
•
Beijing-based biotech InnoCare Pharma (HKG: 9969; SHA: 688428) has released its financial report for the third quarter of 2024, ending September 30, 2024, along with operational updates. The company reported revenue of RMB 698 million (USD 96.9 million) for the first three quarters, marking a 29.8% increase over the same…
•
US generics giant Viatris (NASDAQ: VTRS) has published its financial report for the third quarter of 2024, revealing a 5% year-on-year (YOY) decrease in global sales to USD 3.8 billion in constant currency terms. The report indicates that generics and brand sales fell by 2% and 6% respectively, reaching USD…
•
Gilead Sciences Inc., (NASDAQ: GILD), a major US-based pharmaceutical company, has released its financial results for the third quarter of 2024, showing a 7% year-on-year (YOY) increase in product sales to USD 7.515 billion. Excluding sales of the COVID-19 drug Veklury (remdesivir), the figure stands at a 7% YOY increase…
•
Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has released its financial results for the third quarter of 2024. The company reported revenues of DKK 204.72 billion (USD 29.459 billion) for the first nine months, marking a 24% year-on-year (YOY) growth in constant currency terms. Diabetes and Obesity Care Drive…
•
Germany-based medical device giant Siemens Healthineers AG (ETR: SHL) has released its financial results for the fourth quarter of fiscal 2024, ended September 30, 2024, and the full fiscal year 2024. The company achieved its targets for revenue growth and earnings per share for FY2024, demonstrating resilience amidst challenging market…
•
Germany-based Fresenius Medical Care (FRA: FMEA) has released its financial report for the third quarter of 2024. The total revenues for the quarter reached EUR 4.76 billion, marking a year-on-year (YOY) decrease of 2% in constant exchange rate terms. The operating income saw a significant rise, increasing by 43% YOY…
•
Takeda (TYO: 4502) has released its earnings results for the first half of fiscal year 2024, reporting a 5% year-on-year (YOY) increase in global revenues at constant exchange rates (CER), reaching JPY 2.38 trillion (USD 15.63 billion). The core operating profit margin expanded to 30.2%, marking a 2.2 percentage point…
•
US pharmaceutical giant Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial report for the third quarter of 2024, highlighting a 4% year-on-year (YOY) increase in revenues to USD 1.67 billion. The Pharmaceutical sector experienced a 5% YOY growth, reaching USD 14.943 billion, while the Animal Health…
•
US-based Regeneron Pharmaceuticals (NASDAQ: REGN) has reported its financial details for the third quarter of 2024, with revenues reaching USD 3.72 billion, marking an 11% increase year-on-year (YOY). Product sales grew by 9% YOY to USD 1.946 billion, while collaboration revenues stood at USD 1.774 billion, up 12.5% YOY. In…
•
US biotechnology company Biogen Inc. (NASDAQ: BIIB) reported global sales of USD 2.466 billion for the third quarter of 2024, marking a 3% year-on-year (YOY) decrease in operational terms. Despite this, Biogen increased its full-year 2024 financial guidance, with non-GAAP diluted EPS now expected to range between USD 16.10 and…